FX.co ★ Bayer Submits EU Marketing Authorization Application For Elinzanetant To Treat Hot Flashes In Women

Bayer AG has announced its submission of a marketing authorization application for Elinzanetant to the European Medicines Agency (EMA). This application is for the use of Elinzanetant in the treatment of vasomotor symptoms, commonly known as hot flashes, which affect women. Elinzanetant is a dual antagonist targeting neurokinin-1 and neurokinin-3 receptors and is undergoing late-stage clinical trials for the non-hormonal management of moderate to severe vasomotor symptoms. The submission to the EMA is supported by data from the Phase III OASIS development program. Hot flashes are associated with a decline in estrogen levels, which can occur due to the natural menopause process or through medical interventions that affect ovarian function.